Phenytoin remains one of the most commonly prescribed anticonvulsants despite its first introduction into clinical use over 50 years ago. It is, however, poorly water soluble and this property gives rise to inherent bioavailability problems.' 2 The use of generic formulations has been encouraged because of concern about escalating health care costs. Before prescribing a generic product, however, the physician needs to be assured that the product is bioequivalent to proprietary formulations and other generic formulations. 3 The clinical relevance of inequivalence between formulations was first highlighted by an outbreak of [11] [12] [13] [14] [15] [16] [17] [18] There have been three comparative studies in the UK dealing with the issue of the bioavailability of generic phenytoin tablets. Two described steady state plasma levels at one or two time points in epileptic patients, and gave conflicting results. ' Seventeen patients regularly attending the Epilepsy Unit took part, 11 women and 6 men. Their ages varied between 18 and 67 years and they were all within i 20% of their ideal body weight. All were on maintenance treatment with phenytoin only in or in combination with one or more other anticonvulsants. The daily dose varied from 200-500 mg between patients, but for each individual the doses of all drugs were kept unaltered throughout the study. The sequence of formulations was determined randomly, and was kept undisclosed to monitoring clinicians. Daily doses were standardised for all patients into twice daily doses (12 hourly) and compliance was checked by tablet counts and dose diaries. The study was approved by the local Ethics Committee.
Blood samples were collected predose and hourly for 12 hours. Plasma was separated by centrifugation and was frozen at -20°C until analysis. Phenytoin concentration was measured by an in house HPLC method. The coefficient ofvariation of the assay was < 4% at levels of 5-20 mg/l. Calibration curves for phenytoin were constructed daily during the course of these studies. All curves afforded a correlation coefficient of 0 999 or better.
The following pharmacokinetic parameters were calculated from the raw data: Tirm C max-Observed maximum plasma concentration (mg/l) (extracted directly from raw data) Fluctuation No significant differences were seen between formulations but differences between patients were significant (p < 0-02).
Side effects and seizure frequency No statistically significant differences were found when comparing the incidence of side effects and seizure frequency during the seven treatments. The side effects commonly experienced were No significant differences were seen in seizure control during the seven different treatments. This is probably due to the fact that a four week treatment period is too short for assessment of efficacy of therapy. However, this was not the primary aim of the study.
We conclude that substitution of one generic formulation of phenytoin for another or for Epanutin capsules in the UK may be associated with a change in bioavailability of a magnitude that is likely to cause changes in seizure control or incidence of adverse effects. In-house testing in the manufacturing company using in vitro techniques may not be sensitive enough to detect clinically-important differences in vivo. Although in the case of the Regent tablet, deficiencies were detected inhouse, and led to withdrawal of the formulation, we believe that wider use should be made of in vivo bioavailability testing following any variation in the manufacturing process. In vitro tests may, however, be adequate for batch to batch quality control.
The British National Formulary warns that different brands of phenytoin tablets may not be interchangeable with one another. This warning should be heeded by clinicians who prescribe phenytoin and by pharmacists who stock and dispense the drug.
